Biocon has received an approval to initiate the process to list its subsidiary, Syngene International. The company would offload 10%-15% of its stake through an offer for sale. The board of directors at their meeting held on January 22, 2015 has approved for the same.
Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.